Can I have meningitis from Mean Corpuscular Volume (MCV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: March 31, 2025 • View editorial policy

From the Guidelines

No, you cannot get meningitis from the MCV (Meningococcal Conjugate Vaccine), as it is designed to protect against meningococcal disease, including meningitis caused by certain serogroups of Neisseria meningitidis bacteria. The vaccine contains only parts of the bacteria, not live or weakened bacteria, so it cannot cause the disease itself 1. According to the UK Joint Specialist Societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults, the incidence of meningococcal disease has declined over the last decade in the UK, following the introduction of the group C vaccine and the natural variation of meningococci 1.

Some key points to consider:

  • The MCV is specifically designed to protect against meningococcal disease, including meningitis caused by certain serogroups of Neisseria meningitidis bacteria (typically A, C, W, and Y) 1.
  • The vaccine contains only parts of the bacteria, not live or weakened bacteria, so it cannot cause the disease itself 1.
  • Like any vaccine, MCV may cause mild side effects such as pain at the injection site, low-grade fever, or fatigue, but these typically resolve within a day or two.
  • If you're experiencing symptoms that concern you after vaccination, such as severe headache, stiff neck, high fever, or confusion, you should seek medical attention immediately as these could indicate a different medical condition unrelated to the vaccine 1.

It's worth noting that the guideline highlights the importance of considering a range of factors when determining the likelihood of a specific aetiology, including age, immune status, and exposure history 1. However, the MCV is considered very safe and is routinely recommended for adolescents, with a first dose at age 11-12 and a booster at age 16, as well as for certain high-risk groups 1.

From the Research

Meningitis and MCV

  • MCV typically refers to the Mean Corpuscular Volume, which is a measure of the average size of red blood cells.
  • There is no direct evidence in the provided studies that links MCV to meningitis.
  • Meningitis is typically caused by bacterial, viral, or fungal infections, and its treatment usually involves antibiotics or antiviral medications.

Treatment of Meningitis

  • The provided studies discuss the treatment of bacterial meningitis using various antibiotics, including ceftriaxone 2, 3, 4, 5 and cefotaxime 2, 3, 5.
  • Ceftriaxone is shown to be effective in treating bacterial meningitis in adults and children, with a high cure rate and minimal side effects 2, 4, 5.
  • The use of ceftriaxone in combination with other medications, such as dexamethasone, has also been studied, with mixed results 6.

Conclusion Not Provided

As per the instructions, no conclusion will be provided. The information above is a summary of the provided studies, and it is recommended to consult a medical professional for any questions or concerns about meningitis or MCV.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.